Rosen Law Firm Investigates Potential Securities Class Action Against Disc Medicine, Inc.
Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON). The investigation concerns allegations that the company may have issued materially misleading business information to investors.
New York, NY – July 27, 2026 – Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON). The investigation centers on allegations that Disc Medicine may have issued materially misleading business information to the investing public.
The inquiry follows a Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) on February 13, 2026. The CRL stated that the FDA could not approve Disc Medicine's new drug application for its bitopertin program due to uncertainties requiring additional evidence.
Following this news, Disc Medicine's stock price declined by 22% on February 13, 2026. Investors who purchased Disc Medicine securities may be entitled to compensation without out-of-pocket costs through a contingency fee arrangement as a class action is being prepared.
Rosen Law Firm encourages investors to contact them for more information regarding the potential class action. The firm specializes in securities class actions and shareholder derivative litigation, and has a history of recovering funds for investors.